Trial intelligence / Profile preview

Real-world study of pyrotinib-based first-line therapy in HER2-positive advanced breast cancer

ChiCTR2000038072Phase 4Recruiting

Sponsor

Changhai Hospital

Start

Oct 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1